Karyopharm Therapeutics (NASDAQ:KPTI) had its price target decreased by Wedbush from $19.00 to $14.00 in a research note issued to investors on Monday, The Fly reports. Wedbush currently has an outperform rating on the stock.
Several other equities analysts have also recently commented on KPTI. BidaskClub cut shares of Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Thursday, November 1st. HC Wainwright restated a buy rating and issued a $30.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, November 7th. ValuEngine cut shares of Karyopharm Therapeutics from a buy rating to a hold rating in a research report on Monday, November 12th. B. Riley started coverage on shares of Karyopharm Therapeutics in a research report on Friday, November 30th. They issued a buy rating and a $23.00 target price for the company. Finally, Bank of America upgraded shares of Karyopharm Therapeutics from an underperform rating to a neutral rating in a research report on Thursday, January 3rd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $19.91.
Get Karyopharm Therapeutics alerts:Shares of NASDAQ KPTI traded down $0.01 during mid-day trading on Monday, reaching $4.12. 2,563 shares of the company were exchanged, compared to its average volume of 1,593,887. Karyopharm Therapeutics has a twelve month low of $4.02 and a twelve month high of $21.71. The stock has a market cap of $248.27 million, a PE ratio of -1.42 and a beta of 3.42.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, February 28th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.09). Karyopharm Therapeutics had a negative return on equity of 104.50% and a negative net margin of 502.90%. On average, equities analysts anticipate that Karyopharm Therapeutics will post -3.05 EPS for the current fiscal year.
In other news, insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, December 7th. The shares were sold at an average price of $10.11, for a total value of $126,375.00. Following the transaction, the insider now owns 726,010 shares in the company, valued at approximately $7,339,961.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ltd Chione sold 800,000 shares of the business’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $4.99, for a total transaction of $3,992,000.00. The disclosure for this sale can be found here. Insiders sold a total of 2,306,643 shares of company stock worth $11,372,953 in the last 90 days. Corporate insiders own 13.26% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its position in Karyopharm Therapeutics by 70.3% in the second quarter. Bank of America Corp DE now owns 76,448 shares of the company’s stock valued at $1,299,000 after purchasing an additional 31,556 shares in the last quarter. California Public Employees Retirement System bought a new position in Karyopharm Therapeutics in the second quarter valued at $339,000. Northern Trust Corp grew its position in Karyopharm Therapeutics by 51.5% in the second quarter. Northern Trust Corp now owns 601,974 shares of the company’s stock valued at $10,226,000 after purchasing an additional 204,680 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its position in Karyopharm Therapeutics by 35.5% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 647,307 shares of the company’s stock valued at $11,024,000 after purchasing an additional 169,616 shares in the last quarter. Finally, Emerald Advisers Inc. PA grew its position in Karyopharm Therapeutics by 23.6% in the third quarter. Emerald Advisers Inc. PA now owns 694,068 shares of the company’s stock valued at $11,820,000 after purchasing an additional 132,751 shares in the last quarter. Institutional investors own 75.79% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Recommended Story: How do candlesticks reflect price movement?
No comments:
Post a Comment